Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04741152 |
| Other study ID # |
1899898189bf |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 2010 |
| Est. completion date |
December 2020 |
Study information
| Verified date |
February 2021 |
| Source |
Vishnevsky Center of Surgery |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The blinded resection avoided in case of pancreatic insulinoma
Description:
Despite of the technique and technology developement there are still a lot of troubles to
verify small benign-looking pancreatic NETs. It can be especially important in case of
insulinoma. The organic hyperilsulinism and severe hypoglicemia causeb by the
insulin/proinsulin - producing lesion can lead to severe complications and evem death.
There are some cases of the blinded resections of the pancreas in patients with the "hidden"
insulinoma when the tumor can't be revealed during the preoperative diagnostics and
intraoperatively. Unfortunately, blind resection do not solve the problem of the hypoglicemia
but also cause the specific pancreatic complications.
